Seaweeds are traditional food ingredients mainly in seaside regions. Modern food science and nutrition researchers have identified seaweed as a source of functional nutrients, such as dietary soluble and insoluble fibers, proteins, omega-3 fatty acids, prebiotic polysaccharides, polyphenols, and carotenoids. Owing to the rich nutrients, seaweeds and seaweed extract can be used as functional ingredients by modifying the nutrients composition to reduce the proportion of available carbohydrates, delaying the gastric emptying time and the absorption rate of glucose by increasing the digesta viscosity, and attenuating the digesting rate by blocking the activity of digestive enzymes. This review presents the concept of using seaweed as unconventional ingredients that can function synergistically to reduce the glycemic potency of cereal products.

Alzheimer’s disease (AD) is a neurodegenerative disorder of an ever-increasing aging population with various pathological features such as β-amyloid (Aβ) aggregation, oxidative stress, an impaired cholinergic system, and neuroinflammation. Several therapeutic drugs have been introduced to slow the progression of AD by targeting the above-mentioned pathways. In addition, emerging evidence suggests that naturally occurring compounds have the potential to serve as adjuvant therapies to alleviate AD symptoms. Carotenoids, a group of natural pigments with antioxidative and anti-inflammatory properties, are proposed to be implicated in neuroprotection. To obtain a comprehensive picture of the effect of carotenoids on AD prevention and development, we critically reviewed and discussed recent evidence from in silico, in vitro, in vivo, and human studies in databases including PubMed, Web of Science, Google Scholar, and Cochrane (CENTRAL). After analyzing the existing evidence, we found that high-quality randomized controlled trials (RCTs) are lacking to explore the neuroprotective role of carotenoids in AD pathogenesis and symptoms, especially carotenoids with solid preclinical evidence such as astaxanthin, fucoxanthin, macular carotenoids, and crocin, in order to develop effective preventive dietary supplements for AD patients to ameliorate the symptoms. This review points out directions for future studies to advance the knowledge in this field.

No abstract

Scope: Iron deficiency anemia (IDA) in children is one of the most common nutrition-related health conditions worldwide. Prebiotic oligosaccharides, fructo-oligosaccharide (FOS) and galacto-oligosaccharides (GOS), have shown to affect iron absorption in anemic subjects, but the results in previous studies are inconsistent, thus the underlying mechanism and the effective dose of GOS in mitigating anemia remain unclear. Methods and Results: The present study aims to investigate the mechanism of how GOS/FOS affect iron absorption in an iron-deficient growing rat model from the perspectives of protein expression and gut microbiota, and determine the optimum dose of GOS. Iron-deficient models are established by providing young rats diet without iron addition for 14 days. Later, iron-deficient rats are provided with standard rat chows supplemented with 0%, 3%, 5%, 10% GOS, and 10% FOS for 21 days. The results show that ≥5% GOS supplementation in diet improves iron status and significantly impacts iron-binding/transport protein expression. Furthermore, a dose-dependent modulating effect of GOS on gut microbiota is determined. Conclusion: For the first time, the present study provides evidence that GOS supplementation induces a dose-response effect on iron absorption and gut microbiota in the established model, suggesting a positive role of GOS in ameliorating IDA in children.